AK117-101
01 Jun 2021
AK117-101
NCT04349969
Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody
Akeso
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2020-04-20 |
Anticipated End Date | 2023-09-01 |
Hospital | Icon Cancer Centre Adelaide |
---|---|
Clinical Trial Coordinator | Sue Yeend |
sue.yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Dr Anna Mislang |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs